Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Roivant Sciences Ltd. (ROIV) Insider Trading Activity
Healthcare • Biotechnology • 908 employees
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
Total Value
$231,263,366.75
Total Shares
10,652,964
Average Trade Value
$3,042,939.04
Most Active Insider
Roivant Sciences Ltd.
Total Activity: $336,900,200
Largest Single Transaction
$336,900,200
by Roivant Sciences Ltd. on Jan 13, 2025
30-Day Activity
13 Transactions
Volume: 16,826,259 shares
Value: $335,918,917
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
CFO
|
Jan 28, 2025 | 1,896 | $21,140 | 270,680 (-0.7%) | Payment of Exercise Price | |
| Jan 23, 2025 | 313 | $3,509 | 99,929 (-0.3%) | Payment of Exercise Price | ||
| Jan 23, 2025 | 2,386 | $10,000 | 100,242 (+2.4%) | Grant | ||
| Jan 23, 2025 | 180 | $2,018 | 39,529 (-0.5%) | Payment of Exercise Price | ||
| Jan 23, 2025 | 1,672 | $10,000 | 39,709 (+4.2%) | Grant | ||
| Jan 23, 2025 | 1,248 | $10,000 | 94,913 (+1.3%) | Grant | ||
| Jan 23, 2025 | 306 | $3,430 | 94,607 (-0.3%) | Payment of Exercise Price | ||
|
President COO
|
Jan 21, 2025 | 100,000 | $385,000 | 832,294 (+12.0%) | Exercise/Conversion | |
|
President COO
|
Jan 21, 2025 | 100,000 | $1,128,000 | 732,294 (-13.7%) | Sale | |
|
Chief Accounting Officer
|
Jan 20, 2025 | 1,057 | $11,786 | 203,264 (-0.5%) | Payment of Exercise Price | |
|
CEO
|
Jan 20, 2025 | 11,623 | $129,596 | 17,327,546 (-0.1%) | Payment of Exercise Price | |
|
President COO
|
Jan 20, 2025 | 8,682 | $96,804 | 732,294 (-1.2%) | Payment of Exercise Price | |
| Jan 13, 2025 | 16,845,010 | $336,900,200 | 96,650,341 (+17.4%) | Purchase | ||
|
President COO
|
Dec 30, 2024 | 250,000 | $962,500 | 918,680 (+27.2%) | Exercise/Conversion | |
|
President COO
|
Dec 30, 2024 | 177,704 | $2,050,704 | 740,976 (-24.0%) | Sale | |
|
CFO
|
Dec 28, 2024 | 1,896 | $22,373 | 272,576 (-0.7%) | Payment of Exercise Price | |
|
President COO
|
Dec 27, 2024 | 250,000 | $962,500 | 845,580 (+29.6%) | Exercise/Conversion | |
|
President COO
|
Dec 27, 2024 | 176,900 | $2,090,958 | 668,680 (-26.5%) | Sale | |
|
Preschief Investment Officer
|
Dec 26, 2024 | 689,495 | $2,654,556 | 19,526,042 (+3.5%) | Exercise/Conversion | |
|
Preschief Investment Officer
|
Dec 26, 2024 | 689,495 | $8,280,835 | 18,836,547 (-3.7%) | Sale | |
|
Preschief Investment Officer
|
Dec 24, 2024 | 185,946 | $2,231,352 | 18,836,547 (-1.0%) | Sale | |
|
Preschief Investment Officer
|
Dec 24, 2024 | 185,946 | $715,892 | 19,022,493 (+1.0%) | Exercise/Conversion | |
|
Preschief Investment Officer
|
Dec 23, 2024 | 10,796 | $129,552 | 18,836,547 (-0.1%) | Sale | |
|
Preschief Investment Officer
|
Dec 23, 2024 | 10,796 | $41,565 | 18,847,343 (+0.1%) | Exercise/Conversion | |
|
Chief Accounting Officer
|
Dec 20, 2024 | 3,087 | $35,717 | 204,321 (-1.5%) | Payment of Exercise Price | |
|
CFO
|
Dec 20, 2024 | 2,129 | $24,633 | 274,472 (-0.8%) | Payment of Exercise Price | |
|
CEO
|
Dec 20, 2024 | 10,945 | $126,634 | 17,339,169 (-0.1%) | Payment of Exercise Price | |
|
President COO
|
Dec 20, 2024 | 100,000 | $1,149,000 | 595,580 (-16.8%) | Sale | |
|
President COO
|
Dec 20, 2024 | 100,000 | $385,000 | 695,580 (+14.4%) | Exercise/Conversion | |
|
President COO
|
Dec 20, 2024 | 10,945 | $126,634 | 595,580 (-1.8%) | Payment of Exercise Price | |
|
Preschief Investment Officer
|
Dec 18, 2024 | 412,584 | $4,971,637 | 18,836,547 (-2.2%) | Sale | |
|
Preschief Investment Officer
|
Dec 18, 2024 | 412,584 | $1,588,448 | 19,249,131 (+2.1%) | Exercise/Conversion | |
|
CFO
|
Nov 28, 2024 | 2,341 | $29,707 | 276,601 (-0.8%) | Payment of Exercise Price | |
|
President COO
|
Nov 20, 2024 | 100,000 | $1,132,000 | 606,525 (-16.5%) | Sale | |
|
CEO
|
Nov 20, 2024 | 10,945 | $125,758 | 17,350,114 (-0.1%) | Payment of Exercise Price | |
|
President COO
|
Nov 20, 2024 | 10,945 | $125,758 | 606,525 (-1.8%) | Payment of Exercise Price | |
|
Chief Accounting Officer
|
Nov 20, 2024 | 958 | $11,007 | 207,408 (-0.5%) | Payment of Exercise Price | |
|
President COO
|
Nov 20, 2024 | 100,000 | $385,000 | 706,525 (+14.2%) | Exercise/Conversion | |
|
CFO
|
Oct 28, 2024 | 2,341 | $27,717 | 278,942 (-0.8%) | Payment of Exercise Price | |
| Oct 21, 2024 | 1,231 | $10,000 | 93,665 (+1.3%) | Grant | ||
| Oct 21, 2024 | 1,613 | $10,000 | 38,037 (+4.2%) | Grant | ||
| Oct 21, 2024 | 2,303 | $10,000 | 97,856 (+2.4%) | Grant | ||
|
President COO
|
Oct 21, 2024 | 100,000 | $1,165,000 | 617,470 (-16.2%) | Sale | |
|
President COO
|
Oct 21, 2024 | 100,000 | $385,000 | 717,470 (+13.9%) | Exercise/Conversion | |
|
President COO
|
Oct 20, 2024 | 10,945 | $130,464 | 617,470 (-1.8%) | Payment of Exercise Price | |
|
CEO
|
Oct 20, 2024 | 10,945 | $130,464 | 17,361,059 (-0.1%) | Payment of Exercise Price | |
|
Chief Accounting Officer
|
Oct 20, 2024 | 956 | $11,396 | 208,366 (-0.5%) | Payment of Exercise Price | |
|
CFO
|
Sep 28, 2024 | 2,340 | $26,863 | 281,283 (-0.8%) | Payment of Exercise Price | |
| Sep 26, 2024 | 876,000 | $10,354,320 | 22,179,358 (-3.9%) | Sale | ||
| Sep 26, 2024 | 876,000 | $10,354,320 | 22,179,358 (-3.9%) | Sale | ||
| Sep 25, 2024 | 134,948 | $1,587,704 | 1,277,178 (-10.6%) | Sale | ||
| Sep 25, 2024 | 991,593 | $11,666,389 | 4,731,830 (-21.0%) | Sale | ||
| Sep 25, 2024 | 50,000 | $588,500 | 23,055,358 (-0.2%) | Sale | ||
| Sep 25, 2024 | 365,551 | $4,300,817 | 1,713,508 (-21.3%) | Sale | ||
| Sep 25, 2024 | 50,000 | $588,500 | 23,055,358 (-0.2%) | Sale | ||
| Sep 24, 2024 | 577,186 | $6,709,787 | 2,079,059 (-27.8%) | Sale | ||
| Sep 24, 2024 | 368,052 | $4,278,605 | 1,412,126 (-26.1%) | Sale | ||
| Sep 24, 2024 | 1,565,670 | $18,200,914 | 5,723,423 (-27.4%) | Sale | ||
|
Chief Accounting Officer
|
Sep 23, 2024 | 250,000 | $2,972,500 | 209,322 (-119.4%) | Sale | |
|
Chief Accounting Officer
|
Sep 23, 2024 | 250,000 | $962,500 | 459,322 (+54.4%) | Exercise/Conversion | |
|
CEO
|
Sep 23, 2024 | 1,983,257 | $23,382,600 | 17,870,543 (-11.1%) | Sale | |
|
CEO
|
Sep 23, 2024 | 1,550,000 | $5,967,500 | 19,853,800 (+7.8%) | Exercise/Conversion | |
|
Chief Accounting Officer
|
Sep 20, 2024 | 3,087 | $36,951 | 209,322 (-1.5%) | Payment of Exercise Price | |
|
CEO
|
Sep 20, 2024 | 10,945 | $131,012 | 18,303,800 (-0.1%) | Payment of Exercise Price | |
|
CFO
|
Sep 20, 2024 | 2,129 | $25,484 | 283,623 (-0.8%) | Payment of Exercise Price | |
|
President COO
|
Sep 20, 2024 | 10,945 | $131,012 | 628,415 (-1.7%) | Payment of Exercise Price | |
| Sep 10, 2024 | 16,406 | $10,000 | 7,291,692 (+0.2%) | Grant | ||
| Sep 10, 2024 | 16,406 | $10,000 | 30,270 (+54.2%) | Grant | ||
| Sep 10, 2024 | 16,406 | $10,000 | 95,490 (+17.2%) | Grant | ||
| Sep 10, 2024 | 16,406 | $10,000 | 1,780,178 (+0.9%) | Grant | ||
| Sep 10, 2024 | 16,406 | $10,000 | 99,040 (+16.6%) | Grant | ||
| Sep 10, 2024 | 16,406 | $10,000 | 40,669 (+40.3%) | Grant | ||
|
CFO
|
Aug 28, 2024 | 2,341 | $28,092 | 285,752 (-0.8%) | Payment of Exercise Price | |
|
CEO
|
Aug 20, 2024 | 10,947 | $125,672 | 18,314,745 (-0.1%) | Payment of Exercise Price | |
|
Chief Accounting Officer
|
Aug 20, 2024 | 958 | $10,998 | 212,409 (-0.5%) | Payment of Exercise Price | |
|
President COO
|
Aug 20, 2024 | 10,947 | $125,672 | 639,360 (-1.7%) | Payment of Exercise Price |